J Urol:局部高等级前列腺癌的初步治疗中,手术治疗和放射治疗癌症特异性死亡率评估

2019-01-02 AlexYang MedSci原创

年龄稍小男性中局部高等级前列腺癌的最优初始治疗手段仍旧是有争议的。最近,有研究人员比较了起始根治性前列腺切除和放射治疗对小于60岁男性生存结果的影响。研究包括了2228名男性,其中1459名(65.5%)经历了起始手术治疗,平均跟踪调查的时间为43个月,769名(34.5%)男性经历了体外放射治疗,带有或者不带有近距离放射治疗,平均跟踪调查的时间为44个月。在多变量分析中,在控制了年龄、生物活检格

年龄稍小男性中局部高等级前列腺癌的最优初始治疗手段仍旧是有争议的。最近,有研究人员比较了起始根治性前列腺切除和放射治疗对小于60岁男性生存结果的影响。

研究包括了2228名男性,其中1459名(65.5%)经历了起始手术治疗,平均跟踪调查的时间为43个月,769名(34.5%)男性经历了体外放射治疗,带有或者不带有近距离放射治疗,平均跟踪调查的时间为44个月。在多变量分析中,在控制了年龄、生物活检格林森评分和前列腺特异性抗原等变量后,与起始治疗使用放射治疗相比,起始治疗使用手术治疗的与前列腺癌特异性和总生存率的改善相关(HR 0.37, 95% CI 0.19-0.74, p=0.005 vs HR 0.41, 95% CI 0.24-0.70, p=0.001)。

最后,研究人员指出,他们的数据表明了年轻男性高等级前列腺癌患者中,使用手术治疗要比放射治疗具有显著更好的生存率。研究人员也指出,进一步的前瞻性随机试验是需要的,从而进一步确认这些治疗方法的长期结果情况。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2080493, encodeId=e25b20804938f, content=<a href='/topic/show?id=d14932216cb' target=_blank style='color:#2F92EE;'>#初步治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32216, encryptionId=d14932216cb, topicName=初步治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Wed Jan 23 11:45:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899265, encodeId=3e3018992652a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jun 28 08:45:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290664, encodeId=c90c129066495, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Fri Jan 04 03:45:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405884, encodeId=eae3140588497, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Fri Jan 04 03:45:00 CST 2019, time=2019-01-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2080493, encodeId=e25b20804938f, content=<a href='/topic/show?id=d14932216cb' target=_blank style='color:#2F92EE;'>#初步治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32216, encryptionId=d14932216cb, topicName=初步治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Wed Jan 23 11:45:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899265, encodeId=3e3018992652a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jun 28 08:45:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290664, encodeId=c90c129066495, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Fri Jan 04 03:45:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405884, encodeId=eae3140588497, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Fri Jan 04 03:45:00 CST 2019, time=2019-01-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2080493, encodeId=e25b20804938f, content=<a href='/topic/show?id=d14932216cb' target=_blank style='color:#2F92EE;'>#初步治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32216, encryptionId=d14932216cb, topicName=初步治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Wed Jan 23 11:45:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899265, encodeId=3e3018992652a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jun 28 08:45:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290664, encodeId=c90c129066495, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Fri Jan 04 03:45:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405884, encodeId=eae3140588497, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Fri Jan 04 03:45:00 CST 2019, time=2019-01-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2080493, encodeId=e25b20804938f, content=<a href='/topic/show?id=d14932216cb' target=_blank style='color:#2F92EE;'>#初步治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32216, encryptionId=d14932216cb, topicName=初步治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Wed Jan 23 11:45:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899265, encodeId=3e3018992652a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri Jun 28 08:45:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290664, encodeId=c90c129066495, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Fri Jan 04 03:45:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405884, encodeId=eae3140588497, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Fri Jan 04 03:45:00 CST 2019, time=2019-01-04, status=1, ipAttribution=)]
    2019-01-04 chg122

相关资讯

Nutrients:膳食锌和前列腺癌风险研究

锌是正常前列腺代谢的一种关键微量元素,在恶性肿瘤细胞中减少。然而,膳食锌与前列腺癌(PCa)之间的相关性在流行病学中仍旧是有争议的。最近,有研究人员在一个西班牙案例对照研究MCC研究中探索了上述关系,并考虑了肿瘤恶化和扩展情况,以及PC遗传敏感位点。研究总共包括了733名案例和1228名对照。研究人员使用一个食物频率调查问卷来评估膳食锌,并利用基于单核苷酸多态性的多基因分线评分(PRS)对遗传敏感

Oncogene:雄激素信号对起始于前列腺基层细胞的前列腺癌的发展是必需的

越来越多的证据表明前列腺基层细胞和腔细胞均能够起始致癌性转化。然而,尽管肿瘤起始细胞具有多态性,大多数前列腺癌细胞表达雄激素受体(AR)并且依赖于雄激素进行生长和扩张,表明了雄激素信号在前列腺致癌过程中的必要角色。前列腺基底细胞能够表达p63并且能够分化成为腔内、神经内分泌和基底细胞。最近,有研究人员直接评估了雄激素信号在前列腺p63表达细胞起始的致癌性转化和肿瘤形成中的必要角色。研究人员使用了新

盘点:前列腺癌机理盘点

【1】Brit J Cancer:激素原发性多病灶前列腺癌和匹配的淋巴结转移转录组探索 目前对原发性前列腺癌(PC)预测能力的不足将会导致该疾病发生转移,同样导致良性PCs的过度治疗和恶性PCs的治疗不足。最近,有研究人员探索了多病灶激素原发性PC转移过程发生过程中的转录变化情况。研究人员使用了RNA测序的方法分析了23个激光显微切割原发性PC病灶位点和23个临近的正常前列腺组织样本

XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果

安斯泰来制药公司和辉瑞公司近日宣布,在评估XTANDI(恩杂鲁胺)的III期ARCHES试验中,与单独使用雄激素剥夺疗法(ADT)相比,XTANDI联合ADT在转移性激素敏感性前列腺癌(mHSPC)男性患者的治疗中达到了其主要终点,显著改善了患者的无进展生存期(rPFS)。

PNAS:在去势难治性前列腺癌中,以雄激素受体信号为靶标的脂肪生成从头抑制研究

前列腺癌恶化的一个标志是通过脂肪酸合成酶(FASN)过表达而引起的脂肪代谢的异常调控。FASN是脂肪酸从头合成的一个关键酶。转移去势难治性前列腺癌(mCRPC)可以通过很多种机制发展为雄激素受体(AR)信号抑制剂的抗性情况,包括了AR变异体V7(AR-V7)的持续性激活。最近,有研究人员开发了一种FASN抑制剂(IPI-9119),并且阐释了选择性的FASN抑制剂能够通过代谢重组拮抗CRPC生长,

盘点:前列腺治疗方法进展

【1】Eur J Cancer Care (Engl):接受新药物治疗的前列腺癌患者的疲劳、治疗满意度和健康相关生活质量研究 临床研究已经阐释了醋酸阿比特龙+强的松(AAP)和恩杂鲁胺(ENZ)在显著改善转移性去势难治性前列腺癌患(mCRPC)者生存中的作用。然而,考虑到患者现实生活中的经历,尤其是考虑到疲劳、治疗满意度和健康生活质量(HRQoL),相关的研究很有限。最近,有研究人员